Literature DB >> 25708216

Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease.

Binsheng Wang1, Yongxian Hu1, Lizhen Liu1, Kaimin Hu1, Ruxiu Tie1, Ying He1, Shan Fu1, Ni Zhu1, Yi Luo1, Xiaohong Yu1, He Huang2.   

Abstract

Chronic graft-versus-host disease (cGVHD) is a critical complication after allogeneic hematopoietic stem cell transplantation. The conditioning therapy has been involved in the impairment of bone marrow (BM) mesenchymal stem/stromal cells (MSCs). However, the potential implication of MSCs in the pathophysiology of cGVHD has not been investigated. We analyzed expanded MSCs from patients with cGVHD and compared them with those from transplantation patients without cGVHD. The MSCs from both groups were of host origin and their reserves were comparable. They showed similar morphology, immunophenotype, population doubling times, self-renewal capacity, differentiation, and migration potential. The immunomodulatory potential of the 2 groups was also identical, they were both capable of inhibiting phytohemagglutinin-activated peripheral blood mononuclear cells (PBMCs) proliferation and inducing regulatory T cells after coculturing with CD4(+) T cells, and the immunosuppressive factors were secreted similarly in both MSCs whether in normal culture or coculture with PBMCs. No significant differences were observed in the cellular senescence and apoptosis between 2 groups. In addition, MSCs from patients with cGVHD displayed normal phenotype and function compared with their counterparts from healthy donors, although reduced frequency in BM mononuclear cell fraction was observed in these patients. Taken together, our results suggest that MSCs do not seem to contribute to the pathogenesis of cGVHD and indicate the feasibility of autologous cell therapy in patients who are not completely responding to standard immunosuppressive therapy for cGVHD.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone marrow; Chronic graft-versus-host disease; Hematopoietic stem cell transplantation; Immunomodulation; Mesenchymal stem cells

Mesh:

Substances:

Year:  2015        PMID: 25708216     DOI: 10.1016/j.bbmt.2015.02.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

1.  mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2.

Authors:  Binsheng Wang; Yu Lin; Yongxian Hu; Wei Shan; Senquan Liu; Yulin Xu; Hao Zhang; Shuyang Cai; Xiaohong Yu; Zhen Cai; He Huang
Journal:  Stem Cell Res Ther       Date:  2017-12-29       Impact factor: 6.832

2.  Wnt/β-catenin signaling mediates the abnormal osteogenic and adipogenic capabilities of bone marrow mesenchymal stem cells from chronic graft-versus-host disease patients.

Authors:  Han-Zhou Qi; Yi-Ling Ye; Yuan Suo; Hong Qu; Hai-Yan Zhang; Kai-Bo Yang; Zhi-Ping Fan; Fen Huang; Li Xuan; Yan-Qiu Chen; Hua Jin; Qi-Fa Liu
Journal:  Cell Death Dis       Date:  2021-03-23       Impact factor: 8.469

Review 3.  Urine-derived induced pluripotent/neural stem cells for modeling neurological diseases.

Authors:  Tianyuan Shi; Martin Cheung
Journal:  Cell Biosci       Date:  2021-05-13       Impact factor: 7.133

4.  Tumor necrosis factor α in aGVHD patients contributed to the impairment of recipient bone marrow MSC stemness and deficiency of their hematopoiesis-promotion capacity.

Authors:  Li Ding; Hong-Mei Ning; Pei-Lin Li; Hong-Min Yan; Dong-Mei Han; Xiao-Li Zheng; Jing Liu; Ling Zhu; Mei Xue; Ning Mao; Zi-Kuan Guo; Heng Zhu; Heng-Xiang Wang
Journal:  Stem Cell Res Ther       Date:  2020-03-17       Impact factor: 6.832

5.  PTPN21 Overexpression Promotes Osteogenic and Adipogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells but Inhibits the Immunosuppressive Function.

Authors:  Huafang Wang; Xiaohang Ye; Haowen Xiao; Ni Zhu; Cong Wei; Xiang Sun; Limengmeng Wang; Binsheng Wang; Xiaohong Yu; Xiaoyu Lai; Shan Fu; He Huang
Journal:  Stem Cells Int       Date:  2019-11-21       Impact factor: 5.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.